Please login or register first to view this content.
Metabolic Disorders Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
NEWS & FEATURES
CDC Updates List of Who Is at Highest Risk for COVID-19
Lumasiran Granted Priority Review for Primary Hyperoxaluria Type 1
Antiobesity Meds May Curb Weight Regain After RYGB
Lonafarnib Gets Priority Review for Progeria, Progeroid Laminopathies
Factors ID’d for Positive SARS-CoV-2 Test Result in Primary Care
Setmelanotide Granted Priority Review for Rare Genetic Obesity Disorders
Update on Potential Risks Associated With Liquid-Filled Intragastric Balloons
Procysbi Delayed-Release Oral Granules Now Available in Packets
Obesity Is Risk Factor for COVID-19 Hospital Admission in <60s
Vutrisiran Fast-Tracked for Polyneuropathy of hATTR Amyloidosis
Koselugo Approved for Inoperable NF1 Plexiform Neurofibromas
ENDO: Liraglutide May Benefit Adolescents With Obesity
Setmelanotide Receives Orphan Drug Status for Alström Syndrome
Inhaled Messenger RNA Treatment Fast-Tracked for Cystic Fibrosis
Gene Therapy for Mucopolysaccharidosis Type IIIA Gets Fast Track Designation
Test for Fragile X Syndrome Screening, Diagnosis Gets FDA Clearance
FDA Approves Procysbi Delayed-Release Oral Granules in Packets
Belviq, Belviq XR Withdrawn From US Market
